FDA Advisers Say Avastin Shouldn’t Be Used for Breast Cancer - Health News - Health.com
Wednesday, July 21st, 2010We recommend:
TUESDAY, July 20 (HealthDay News) — The cancer dose Avastin should no yearner be secondhand as a discussion for front cancer, a U.S. Food and Drug Administration consultive gore voted Tuesday, expression the dose wasn’t benefiting patients.
The 12 to 1 suffrage delineated a blow for Avastin, which is the humans’s best-selling cancer dose, with sales finale year of some $6 1000000000000. Avastin is sold by dose manufacturer Roche’s Genentech whole, The New York Times reported.
